Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 15/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373284 | 0.83 | OPRM1 (0.60) | GRIN2BOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL23357843 | 0.79 | GAA (0.39) | GRIN2BOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL15689661 | 0.79 | OPRM1 (0.48) | OPRM1OPRD1OPRK1OPRL1HDAC4 | |
| SCHEMBL15689473 | 0.79 | SIGMAR1 (0.53) | OPRM1OPRD1OPRK1OPRL1APP | |
| SCHEMBL1311605 | 0.79 | GRIN2B (0.44) | GRIN2B | |
| SCHEMBL1669519 | 0.76 | GRIN2B (0.44) | GRIN2BOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL8175778 | 0.73 | OPRM1 (0.56) | GRIN2BOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL29060516 | 0.73 | OPRM1 (0.59) | GRIN2BOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL8070982 | 0.72 | OPRM1 (0.46) | GRIN2BOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL1812162 | 0.71 | CYP11B2 (0.46) | GRIN2BOPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342194-B1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-9981952-B2 | Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-05-29 | — | — | US | disclosed |
| US-9630949-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-04-25 | — | — | US | disclosed |
| EP-2726478-B1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2017-01-11 | — | — | EP | disclosed |
| US-20160237065-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-08-18 | — | — | US | disclosed |
| US-9353083-B2 | Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-05-31 | — | — | US | disclosed |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-12 | — | — | US | disclosed |
| US-8871187-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereon in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-28 | — | — | US | disclosed |
| US-20140228342-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-14 | — | — | US | disclosed |
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | CYP2D6, CYP51A1, CYP2C19 | GRIN2B 3788/4885OPRM1 686/4885OPRD1 247/4885 |
| US-20160237065-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | MC1R, MCHR1, MCHR2 | GRIN2B 737/4885OPRM1 599/4885OPRD1 756/4885 |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | CYP51A1, TYR, CYP2C19 | GRIN2B 4066/4885OPRM1 495/4885OPRD1 174/4885 |
| US-20140228342-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | MC1R, MCHR1, MCHR2 | GRIN2B 699/4885OPRM1 554/4885OPRD1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.